Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Key facts
- Who runs it
- University of Michigan
- Where
- Ann Arbor, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 8 Dec 2022
- Expected to end
- Dec 2027
- Type of study
- Observational, 3 groups
- Treatments tested
- Biospecimen collection
- Data collection
- Record updated
- 29 April 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Retrospective non-consented participant group had a transplant from the year 2000 and onward
- Diagnosis of FSGS or MCD in the native kidney (prior to transplant)
Who cannot take part
- FSGS or MCD secondary to a known disorder (e.g. lupus nephritis, Immunoglobulin A (IgA) nephropathy, malignancy)
- Pathologic diagnosis other than FSGS or MCD
Where in United States
- University of MichiganAnn Arbor, United StatesContact: Eloise Salmon, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment have been limited by small sample sizes in single center studies and misclassification in registry studies. Recent advances in the understanding of the mechanisms of FSGS in the native kidney has reinvigorated the scientific community to develop a collaborative community to advance research into the epidemiology, mechanisms, interventions, and outcomes.
Read full original descriptionShow less
The purpose of RESOLVE is to gather a group of people with FSGS and MCD that have had or will have a kidney transplant to create a bank of information and biospecimens so researchers can more effectively study these diseases.
The 3 groups in the trial
- Enrolled participants prior to transplant
Participants will be consented.
Treatment: Biospecimen collection and Data collection
- Enrolled participant after transplant
Participants will be consented.
Treatment: Biospecimen collection and Data collection
- Retrospective participant data
Waiver of consent for secondary use of existing data.
Treatment: Data collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD)
- Record updated
- 29 April 2026